$CYRX
Cryoport, Inc.

2019 Q1 Form 10-K Financial Statement

#000114420419013692 Filed on March 13, 2019

View on sec.gov

Income Statement

Concept 2019 Q1 2018 Q4 2018 Q3
Revenue $6.653M $5.691M $5.285M
YoY Change 65.37% 71.31% 75.99%
Cost Of Revenue $3.199M $2.870M $2.549M
YoY Change 73.97% 78.26% 82.6%
Gross Profit $3.454M $2.816M $2.736M
YoY Change 58.12% 64.39% 70.36%
Gross Profit Margin 51.92% 49.48% 51.77%
Selling, General & Admin $5.105M $4.440M $4.434M
YoY Change 39.75% 23.33% 36.44%
% of Gross Profit 147.8% 157.67% 162.06%
Research & Development $489.6K $600.0K $463.4K
YoY Change 48.48% 57.89% 34.39%
% of Gross Profit 14.17% 21.31% 16.94%
Depreciation & Amortization $300.6K $270.0K $210.0K
YoY Change 60.02% 58.82% 16.67%
% of Gross Profit 8.7% 9.59% 7.68%
Operating Expenses $5.594M $5.040M $4.897M
YoY Change 40.47% 26.63% 36.24%
Operating Profit -$2.141M -$2.220M -$2.161M
YoY Change 19.06% -2.25% 8.7%
Interest Expense $338.7K -$70.00K $0.00
YoY Change
% of Operating Profit
Other Income/Expense, Net $91.47K $40.00K $19.68K
YoY Change 480.11% 132.68%
Pretax Income -$2.388M -$2.250M -$2.142M
YoY Change -10.97% -0.88% 8.18%
Income Tax -$900.00 $0.00 $2.102K
% Of Pretax Income
Net Earnings -$2.387M -$2.258M -$2.144M
YoY Change -11.03% -0.53% 8.28%
Net Earnings / Revenue -35.88% -39.68% -40.57%
Basic Earnings Per Share
Diluted Earnings Per Share -$78.52K -$76.69K -$74.38K
COMMON SHARES
Basic Shares Outstanding 30.44M 29.24M shares 28.57M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2019 Q1 2018 Q4 2018 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $47.30M $47.30M $23.70M
YoY Change 148.95% 215.33% 53.9%
Cash & Equivalents $32.77M $37.33M $13.85M
Short-Term Investments $15.10M $10.00M $10.00M
Other Short-Term Assets $700.0K $800.0K $900.0K
YoY Change 40.0% 60.0% 200.0%
Inventory $227.1K $220.5K $130.3K
Prepaid Expenses
Receivables $4.208M $3.544M $3.197M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $52.45M $51.77M $27.94M
YoY Change 137.94% 199.29% 62.47%
LONG-TERM ASSETS
Property, Plant & Equipment $5.125M $4.357M $3.578M
YoY Change 99.22% 73.52% 70.4%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $400.0K $400.0K $400.0K
YoY Change 0.0% 0.0% 0.0%
Total Long-Term Assets $7.345M $4.846M $4.055M
YoY Change 141.46% 63.41% 62.21%
TOTAL ASSETS
Total Short-Term Assets $52.45M $51.77M $27.94M
Total Long-Term Assets $7.345M $4.846M $4.055M
Total Assets $59.79M $56.62M $32.00M
YoY Change 138.37% 179.41% 62.43%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.300M $1.700M $1.900M
YoY Change 76.92% 41.67% 72.73%
Accrued Expenses $2.100M $1.300M $900.0K
YoY Change 90.91% 44.44% 50.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $0.00
YoY Change
Total Short-Term Liabilities $4.532M $3.061M $2.785M
YoY Change 88.83% 39.01% 54.74%
LONG-TERM LIABILITIES
Long-Term Debt $14.70M $14.70M $0.00
YoY Change
Other Long-Term Liabilities $1.600M $300.0K $200.0K
YoY Change 700.0% 50.0% 0.0%
Total Long-Term Liabilities $16.30M $15.00M $200.0K
YoY Change 8050.0% 7400.0% 0.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $4.532M $3.061M $2.785M
Total Long-Term Liabilities $16.30M $15.00M $200.0K
Total Liabilities $20.89M $18.07M $2.965M
YoY Change 693.68% 660.24% 48.25%
SHAREHOLDERS EQUITY
Retained Earnings -$143.4M -$141.0M -$138.7M
YoY Change 6.9% 7.27%
Common Stock $182.3M $179.5M $167.8M
YoY Change 16.41% 20.23%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $38.91M $38.55M $29.03M
YoY Change
Total Liabilities & Shareholders Equity $59.79M $56.62M $32.00M
YoY Change 138.37% 179.41% 62.43%

Cashflow Statement

Concept 2019 Q1 2018 Q4 2018 Q3
OPERATING ACTIVITIES
Net Income -$2.387M -$2.258M -$2.144M
YoY Change -11.03% -0.53% 8.28%
Depreciation, Depletion And Amortization $300.6K $270.0K $210.0K
YoY Change 60.02% 58.82% 16.67%
Cash From Operating Activities -$189.6K -$360.0K -$660.0K
YoY Change -82.17% -70.49% -31.25%
INVESTING ACTIVITIES
Capital Expenditures $1.121M -$1.090M -$870.0K
YoY Change 315.9% 109.62% 278.26%
Acquisitions
YoY Change
Other Investing Activities -$4.510M $0.00 -$9.920M
YoY Change
Cash From Investing Activities -$5.652M -$1.100M -$10.78M
YoY Change 1883.89% 111.54% 4586.96%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $9.800M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.290M 24.93M 5.310M
YoY Change -75.65% 1706.52% 41.98%
NET CHANGE
Cash From Operating Activities -189.6K -360.0K -660.0K
Cash From Investing Activities -5.652M -1.100M -10.78M
Cash From Financing Activities 1.290M 24.93M 5.310M
Net Change In Cash -4.551M 23.47M -6.130M
YoY Change -215.17% -6619.44% -340.39%
FREE CASH FLOW
Cash From Operating Activities -$189.6K -$360.0K -$660.0K
Capital Expenditures $1.121M -$1.090M -$870.0K
Free Cash Flow -$1.311M $730.0K $210.0K
YoY Change -1.69% -204.29% -128.77%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
37327125
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
15042189
CY2018Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
3543666
CY2017Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1625476
CY2018Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
752269
CY2017Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
516427
CY2018Q4 us-gaap Assets Current
AssetsCurrent
51774542
CY2017Q4 us-gaap Assets Current
AssetsCurrent
17298888
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4357498
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2511174
CY2018Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
137220
CY2018Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1709397
CY2018Q4 us-gaap Deposits Assets
DepositsAssets
350837
CY2017Q4 us-gaap Deposits Assets
DepositsAssets
363403
CY2018Q4 us-gaap Assets
Assets
56620097
CY2017Q4 us-gaap Assets
Assets
20264111
CY2017Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
90646
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
30319038
CY2017Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1203354
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3061381
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2202312
CY2018Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
267415
CY2017Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
175033
CY2018Q4 us-gaap Liabilities
Liabilities
18073532
CY2017Q4 us-gaap Liabilities
Liabilities
2377345
CY2018Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2500000
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
30319038
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
25701924
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2017Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
30319
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
25702
CY2018Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
179501577
CY2017Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
149293947
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-140988484
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-131432883
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
38546565
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
17886766
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
56620097
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
20264111
CY2018Q4 us-gaap Short Term Investments
ShortTermInvestments
9930968
CY2017Q4 us-gaap Short Term Investments
ShortTermInvestments
0
CY2018Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
66315
CY2017Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
73444
CY2018Q4 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
14711580
CY2017Q4 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
0
CY2018Q4 us-gaap Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
33156
CY2017Q4 us-gaap Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
0
CY2018Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
100000
CY2017Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
70000
CY2018Q4 us-gaap Convertible Subordinated Debt
ConvertibleSubordinatedDebt
288400
CY2018Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2500000
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
25701924
CY2018 us-gaap Revenues
Revenues
19626453
CY2017 us-gaap Revenues
Revenues
11954267
CY2018 us-gaap Cost Of Revenue
CostOfRevenue
9386188
CY2017 us-gaap Cost Of Revenue
CostOfRevenue
5987834
CY2018 us-gaap Gross Profit
GrossProfit
10240265
CY2017 us-gaap Gross Profit
GrossProfit
5966433
CY2018 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9798793
CY2017 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7420837
CY2018 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
7245644
CY2017 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
5232406
CY2018 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1840443
CY2017Q2 us-gaap Revenues
Revenues
2917000
CY2017 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1205692
CY2018 us-gaap Operating Expenses
OperatingExpenses
18884880
CY2017 us-gaap Operating Expenses
OperatingExpenses
13858935
CY2018 us-gaap Operating Income Loss
OperatingIncomeLoss
-8644615
CY2017 us-gaap Operating Income Loss
OperatingIncomeLoss
-7892502
CY2018 us-gaap Interest Expense
InterestExpense
69253
CY2017 us-gaap Interest Expense
InterestExpense
15693
CY2018 cyrx Warrant Repricing Expense
WarrantRepricingExpense
899410
CY2017 cyrx Warrant Repricing Expense
WarrantRepricingExpense
0
CY2018 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
77631
CY2017 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
14337
CY2018 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-891032
CY2017 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1356
CY2018 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-9535647
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-7893858
CY2018 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
19954
CY2017 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
5143
CY2018Q1 us-gaap Revenues
Revenues
4023000
CY2018Q2 us-gaap Revenues
Revenues
4627000
CY2018Q3 us-gaap Revenues
Revenues
5285000
CY2018Q4 us-gaap Revenues
Revenues
5691000
CY2018Q1 us-gaap Gross Profit
GrossProfit
2184000
CY2018Q2 us-gaap Gross Profit
GrossProfit
2504000
CY2018Q3 us-gaap Gross Profit
GrossProfit
2736000
CY2018Q4 us-gaap Gross Profit
GrossProfit
2816000
CY2018Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-1798000
CY2018Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-2465000
CY2018Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2161000
CY2018Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-2220000
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-2683000
CY2018Q2 us-gaap Net Income Loss
NetIncomeLoss
-2471000
CY2018Q3 us-gaap Net Income Loss
NetIncomeLoss
-2144000
CY2018Q4 us-gaap Net Income Loss
NetIncomeLoss
-2258000
CY2018Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.10
CY2018Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.09
CY2018Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.07
CY2018Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.08
CY2017Q1 us-gaap Revenues
Revenues
2712000
CY2017Q3 us-gaap Revenues
Revenues
3003000
CY2017Q4 us-gaap Revenues
Revenues
3322000
CY2017Q1 us-gaap Gross Profit
GrossProfit
1253000
CY2017Q2 us-gaap Gross Profit
GrossProfit
1393000
CY2017Q3 us-gaap Gross Profit
GrossProfit
1606000
CY2017Q4 us-gaap Gross Profit
GrossProfit
1713000
CY2017Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-1769000
CY2017Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-1864000
CY2017Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-1988000
CY2017Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-2271000
CY2017Q1 us-gaap Net Income Loss
NetIncomeLoss
-1789000
CY2017Q2 us-gaap Net Income Loss
NetIncomeLoss
-1860000
CY2017Q3 us-gaap Net Income Loss
NetIncomeLoss
-1980000
CY2017Q4 us-gaap Net Income Loss
NetIncomeLoss
-2270000
CY2017Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.10
CY2017Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.08
CY2017Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.08
CY2017Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.09
CY2017 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
0
CY2018 us-gaap Other Comprehensive Income Defined Benefit Plans Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent
-23582
CY2017 us-gaap Other Comprehensive Income Defined Benefit Plans Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent
0
CY2018 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-20429
CY2018 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
857939
CY2017 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
664831
CY2018 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
0
CY2017 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
6130
CY2018 us-gaap Share Based Compensation
ShareBasedCompensation
5478625
CY2017 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
0
CY2018 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-9552448
CY2017 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7899001
CY2018Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
16272000
CY2017Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
15307000
CY2018Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
167000
CY2017Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
100000
CY2018Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
2566000
CY2017Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
2014000
CY2018Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
83000
CY2017Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
41000
CY2018Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
19088000
CY2017Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
17462000
CY2018Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2017Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2018 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-2002000
CY2017 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-2684000
CY2018 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-348000
CY2017 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-277000
CY2018 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
472000
CY2017 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
503000
CY2018 cyrx Effective Income Tax Rate Reconciliation Nondeductible Expense Warrant Inducement And Repricing Costs Amount
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseWarrantInducementAndRepricingCostsAmount
189000
CY2017 cyrx Effective Income Tax Rate Reconciliation Nondeductible Expense Warrant Inducement And Repricing Costs Amount
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseWarrantInducementAndRepricingCostsAmount
0
CY2018 us-gaap Income Tax Reconciliation Other Reconciling Items
IncomeTaxReconciliationOtherReconcilingItems
82000
CY2017 us-gaap Income Tax Reconciliation Other Reconciling Items
IncomeTaxReconciliationOtherReconcilingItems
56000
CY2018 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
0
CY2017 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
8032000
CY2018 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
42000
CY2017 us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
8000000
CY2017 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.35
CY2018 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
191670
CY2017 us-gaap Share Based Compensation
ShareBasedCompensation
3547781
CY2018 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-16233
CY2017 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
0
CY2018 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
899410
CY2017 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0
CY2018 us-gaap Disposal Group Not Discontinued Operation Gain Loss On Disposal
DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
-397467
CY2017 us-gaap Disposal Group Not Discontinued Operation Gain Loss On Disposal
DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
-186030
CY2018 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
40215
CY2017 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
11646
CY2018 us-gaap Increase Decrease In Long Term Receivables Current
IncreaseDecreaseInLongTermReceivablesCurrent
1958405
CY2017 us-gaap Increase Decrease In Long Term Receivables Current
IncreaseDecreaseInLongTermReceivablesCurrent
441643
CY2018 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
105718
CY2017 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
25297
CY2018 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
235825
CY2017 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
261489
CY2018 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
405074
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2017 cyrx Proceeds From Atm Net Of Offering Costs
ProceedsFromATMNetOfOfferingCosts
0
CY2018 us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
4641807
CY2017 us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
0
CY2017 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
123249
CY2018 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
336736
CY2017 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
506480
CY2018 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-7129
CY2017 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
0
CY2018 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
66023
CY2017 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
-1843
CY2017 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1714931
CY2017 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
0
CY2017 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
85646
CY2018 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
6020919
CY2017 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
5151660
CY2018 us-gaap Proceeds From Short Term Debt
ProceedsFromShortTermDebt
15000000
CY2017 us-gaap Proceeds From Short Term Debt
ProceedsFromShortTermDebt
0
CY2018 us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
0
CY2017 us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
656221
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4524529
CY2018 us-gaap Interest Paid Net
InterestPaidNet
637
CY2017 us-gaap Interest Paid Net
InterestPaidNet
4744
CY2018 us-gaap Income Taxes Paid
IncomeTaxesPaid
19954
CY2017 us-gaap Income Taxes Paid
IncomeTaxesPaid
5143
CY2017 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
0
CY2018 us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
288420
CY2017 us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
0
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0259
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0307
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.977
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
1.1
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0179
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0223
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
1.11
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
1.15
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2018 cyrx Non Cash Net Unrealised Gain On Available For Sale Securities
NonCashNetUnrealisedGainOnAvailableForSaleSecurities
23582
CY2017 cyrx Non Cash Net Unrealised Gain On Available For Sale Securities
NonCashNetUnrealisedGainOnAvailableForSaleSecurities
0
CY2018 cyrx Leasehold Improvements Paid By Tenant Allowance
LeaseholdImprovementsPaidByTenantAllowance
127316
CY2017 cyrx Leasehold Improvements Paid By Tenant Allowance
LeaseholdImprovementsPaidByTenantAllowance
0
CY2018 cyrx Deferred Offering Costs In Connection With Warrant Repricing
DeferredOfferingCostsInConnectionWithWarrantRepricing
0
CY2017 cyrx Deferred Offering Costs In Connection With Warrant Repricing
DeferredOfferingCostsInConnectionWithWarrantRepricing
31981
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
5680402
CY2017 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3477781
CY2017 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
70000
CY2017 cyrx Stock Issued During Period Value Stock Options And Warrants Exercised
StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised
5151660
CY2018 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
3153
CY2018 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5408625
CY2018 cyrx Stock Issued During Period Shares Cashless Exercise Of Warrants
StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants
155886
CY2018Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
302567
CY2018 cyrx Adjustments To Additional Paid In Capital Warrants Repricing Expenses
AdjustmentsToAdditionalPaidInCapitalWarrantsRepricingExpenses
899410
CY2018 cyrx Stock Issued During Period Value On Net Tender Offer
StockIssuedDuringPeriodValueOnNetTenderOffer
4641807
CY2018 cyrx Proceeds From Atm Net Of Offering Costs
ProceedsFromATMNetOfOfferingCosts
3363156
CY2017 cyrx Stock Issued During Period Shares Cashless Exercise Of Warrants
StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants
144164
CY2017Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
261083
CY2018 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
70000
CY2018 cyrx Warrants Exercised Intrinsic Value
WarrantsExercisedIntrinsicValue
21500000
CY2017 cyrx Warrants Exercised Intrinsic Value
WarrantsExercisedIntrinsicValue
7100000
CY2018 cyrx Stock Issued During Period Value Stock Options And Warrants Exercised
StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised
6020919
CY2018 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
9808330
CY2018Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
3700000
CY2017Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
797600
CY2018 us-gaap Nature Of Operations
NatureOfOperations
<div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Note 1.&#160;Nature of the Business</div></div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.5in; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Cryoport, Inc. (&#8220;Cryoport&#8221;) is the premier provider of temperature controlled logistics solutions to the life sciences industry through its purpose-built proprietary packaging, information technology and specialized cold chain logistics expertise. The Company provides leading edge logistics solutions to the biopharma, reproductive medicine and animal health markets to ship, store and deliver biologic materials, such as immunotherapies, stem cells, CAR-T cell therapies, vaccines and reproductive cells for clients worldwide Cryoport actively&#160;supports pharmaceutical and biotechnology companies, points-of-care, contract research organizations, central laboratories, contract manufacturers, university researchers and other entities service the life sciences industry.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.38in; background: none;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.5in; background: none;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company is a Nevada corporation and its </div><div style="background: none; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">common stock is traded on the NASDAQ Capital Market exchange under the ticker symbol &#8220;CYRX.&#8221;</div></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2018 us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;">Use of Estimates</div></div></div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.34in; background: none;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.5in; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from estimated amounts. The Company&#8217;s significant estimates include the allowance for doubtful accounts, fair value of short-term investments, recoverability of long-lived assets, allowance for inventory obsolescence, deferred taxes and their accompanying valuations, and valuation of equity instruments.</div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2018 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;">Concentrations of Credit Risk</div></div></div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.34in; background: none;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.5in; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash, cash equivalents and short-term investments. From time to time, we maintain cash, cash equivalent and short-term investment balances in excess of amounts insured by the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;) and the Securities Investor Protection Corporation (&#8220;SIPC&#8221;). Primarily all of our cash, cash equivalents and short-term investments at December 31, 2018 were in excess of amounts insured by the FDIC and SIPC. The Company performs ongoing evaluations of these institutions to limit its concentration risk exposure. We manage such risks in our portfolio by investing in highly liquid, highly-rated instruments, and limit investing in long-term maturity instruments.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.34in; background: none;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.5in; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Our investment policy requires that purchased instruments in marketable securities may only be in highly-rated instruments, which are primarily U.S. Treasury bills or treasury-backed securities, and also limits our investment in securities of any single issuer.</div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2018Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
7806839
CY2018 us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;">Reclassifications</div></div></div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.19in; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.5in; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Certain prior year amounts have been reclassified in the consolidated balance sheets to conform to the current year presentation.</div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2018 cyrx Maturity Period Of Highly Liquid Investments
MaturityPeriodOfHighlyLiquidInvestments
P90D
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1000000
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
10.00
CY2018Q4 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
9800000
CY2018Q4 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
192000
CY2018 us-gaap Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
P7Y
CY2018 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-20400
CY2018Q3 us-gaap Sale Of Stock Percentage Of Ownership Before Transaction
SaleOfStockPercentageOfOwnershipBeforeTransaction
0.030
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-9555601
CY2017 us-gaap Net Income Loss
NetIncomeLoss
-7899001
CY2018 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
28210648
CY2017 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
22963382
CY2018 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.34
CY2017 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.34
CY2018Q4 us-gaap Inventory Net
InventoryNet
220514
CY2017Q4 us-gaap Inventory Net
InventoryNet
114796
CY2018Q4 cyrx Cryogenic Shippers And Data Loggers
CryogenicShippersAndDataLoggers
2719973
CY2017Q4 cyrx Cryogenic Shippers And Data Loggers
CryogenicShippersAndDataLoggers
2107642
CY2018Q4 us-gaap Furniture And Fixtures Gross
FurnitureAndFixturesGross
148002
CY2017Q4 us-gaap Furniture And Fixtures Gross
FurnitureAndFixturesGross
63411
CY2018Q4 us-gaap Machinery And Equipment Gross
MachineryAndEquipmentGross
567506
CY2017Q4 us-gaap Machinery And Equipment Gross
MachineryAndEquipmentGross
362476
CY2018Q4 us-gaap Leasehold Improvements Gross
LeaseholdImprovementsGross
1051712
CY2017Q4 us-gaap Leasehold Improvements Gross
LeaseholdImprovementsGross
436620
CY2018Q4 us-gaap Construction In Progress Gross
ConstructionInProgressGross
1374906
CY2018 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5833227
CY2017 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9162082
CY2018 us-gaap Other Expenses
OtherExpenses
44200
CY2018Q4 us-gaap Cash
Cash
37223698
CY2018Q4 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
103427
CY2018Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
47258093
CY2016Q1 us-gaap Stock Issued During Period Shares Conversion Of Convertible Securities
StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
4977038
CY2018Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
7902393
CY2018Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
23582
CY2018Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
0
CY2018Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
7925975
CY2018Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
5913327
CY2018Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
5936515
CY2018Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
1989066
CY2018Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
1989460
CY2016Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
4.50
CY2018 us-gaap Equity Securities Fv Ni Realized Gain Loss
EquitySecuritiesFvNiRealizedGainLoss
-16233
CY2018 cyrx Equity Securities Realized Gain Loss Sold
EquitySecuritiesRealizedGainLossSold
0
CY2018 us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
-16233
CY2018Q4 us-gaap Equity Securities Fv Ni
EquitySecuritiesFvNi
2000000
CY2018Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
123528
CY2017Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
104745
CY2018Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
96986
CY2017Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
10051
CY2017Q4 us-gaap Construction In Progress Gross
ConstructionInProgressGross
568688
CY2018Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
6981387
CY2017Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
4603480
CY2018Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2623889
CY2017Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2092306
CY2018 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
0
CY2017 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
0
CY2018Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
0
CY2018Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
900797
CY2017Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
617984
CY2018Q4 us-gaap Accrued Vacation Current
AccruedVacationCurrent
361681
CY2017Q4 us-gaap Accrued Vacation Current
AccruedVacationCurrent
307530
CY2018Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1262478
CY2017Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
925514
CY2019Q4 us-gaap Debt Instrument Redemption Price Percentage
DebtInstrumentRedemptionPricePercentage
1.12
CY2020Q4 us-gaap Debt Instrument Redemption Price Percentage
DebtInstrumentRedemptionPricePercentage
1.09
CY2020Q4 us-gaap Debt Instrument Redemption Price Percentage
DebtInstrumentRedemptionPricePercentage
1.06
CY2017 cyrx Purchase Of Equipment Through Capital Lease Obligation
PurchaseOfEquipmentThroughCapitalLeaseObligation
0
CY2018 us-gaap Depreciation
Depreciation
857900
CY2017 us-gaap Depreciation
Depreciation
664800
CY2018 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
422600
CY2018Q4 us-gaap Deferred Revenue
DeferredRevenue
66300
CY2017Q4 us-gaap Deferred Revenue
DeferredRevenue
73400
CY2018Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
3153
CY2017Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
0
CY2018 us-gaap Repayments Of Debt And Capital Lease Obligations
RepaymentsOfDebtAndCapitalLeaseObligations
14700
CY2017 us-gaap Repayments Of Debt And Capital Lease Obligations
RepaymentsOfDebtAndCapitalLeaseObligations
0
CY2018 cyrx Purchase Of Equipment Through Capital Lease Obligation
PurchaseOfEquipmentThroughCapitalLeaseObligation
71047
CY2017 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
298500
CY2018Q1 cyrx Class Of Warrant Or Right Number Of Warrants Exercised
ClassOfWarrantOrRightNumberOfWarrantsExercised
1580388
CY2018 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
248839
CY2018Q4 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
23191
CY2018Q4 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
480000
CY2018 us-gaap Debt Instrument Convertible Remaining Discount Amortization Period1
DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1
P5Y
CY2017Q4 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
0
CY2018Q4 us-gaap Capital Leases Future Minimum Payments Due In Three Years
CapitalLeasesFutureMinimumPaymentsDueInThreeYears
8647
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
542790
CY2018Q4 us-gaap Capital Leases Future Minimum Payments Due In Four Years
CapitalLeasesFutureMinimumPaymentsDueInFourYears
0
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
198219
CY2018Q4 us-gaap Capital Leases Future Minimum Payments Due In Five Years
CapitalLeasesFutureMinimumPaymentsDueInFiveYears
0
CY2018Q4 us-gaap Capital Leased Assets Gross
CapitalLeasedAssetsGross
71000
CY2018Q4 us-gaap Capital Leases Lessee Balance Sheet Assets By Major Class Accumulated Deprecation
CapitalLeasesLesseeBalanceSheetAssetsByMajorClassAccumulatedDeprecation
6800
CY2018Q4 us-gaap Property Plant And Equipment Other
PropertyPlantAndEquipmentOther
545445
CY2017Q4 us-gaap Property Plant And Equipment Other
PropertyPlantAndEquipmentOther
545445
CY2018Q4 us-gaap Capitalized Computer Software Gross
CapitalizedComputerSoftwareGross
573843
CY2017Q4 us-gaap Capitalized Computer Software Gross
CapitalizedComputerSoftwareGross
519198
CY2018 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
9808330
CY2017 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
CY2018 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
0
CY2017 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
11405924
CY2017 cyrx Stock Issued During Period Value New Issues Under Offering
StockIssuedDuringPeriodValueNewIssuesUnderOffering
11405924
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
109773
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
525592
CY2018Q4 us-gaap Capital Leases Future Minimum Payments Due Current
CapitalLeasesFutureMinimumPaymentsDueCurrent
25940
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
537742
CY2018Q4 us-gaap Capital Leases Future Minimum Payments Due In Two Years
CapitalLeasesFutureMinimumPaymentsDueInTwoYears
25940
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
538893
CY2018Q4 us-gaap Capital Leases Future Minimum Payments Due Thereafter
CapitalLeasesFutureMinimumPaymentsDueThereafter
0
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
2453009
CY2018Q4 us-gaap Capital Leases Future Minimum Payments Due
CapitalLeasesFutureMinimumPaymentsDue
60527
CY2018 us-gaap Capital Leases Income Statement Interest Expense
CapitalLeasesIncomeStatementInterestExpense
4180
CY2018Q4 us-gaap Capital Leases Future Minimum Payments Present Value Of Net Minimum Payments
CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments
56347
CY2018Q4 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
23191
CY2018 dei Document Type
DocumentType
10-K
CY2018 dei Amendment Flag
AmendmentFlag
false
CY2018 dei Document Period End Date
DocumentPeriodEndDate
2018-12-31
CY2018 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2018
CY2018 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2018 dei Entity Registrant Name
EntityRegistrantName
Cryoport, Inc.
CY2018 dei Entity Central Index Key
EntityCentralIndexKey
0001124524
CY2018 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2018 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2018 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2018 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2018 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2018Q2 dei Entity Public Float
EntityPublicFloat
351453000
CY2018 dei Trading Symbol
TradingSymbol
CYRX
CY2019Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
30436322
CY2018 dei Entity Shell Company
EntityShellCompany
false
CY2018 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2018 dei Entity Small Business
EntitySmallBusiness
true
CY2018 us-gaap Increase Decrease In Deposits
IncreaseDecreaseInDeposits
12576
CY2017 us-gaap Increase Decrease In Deposits
IncreaseDecreaseInDeposits
0
CY2018 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-9554
CY2018 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2914029
CY2018 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
9923619
CY2018 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
46574
CY2018 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3352380
CY2017 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3583126
CY2018 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-12884222
CY2017 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1800577
CY2018 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
38531092
CY2017 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
15901363
CY2018 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
22284936
CY2017 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
10517660
CY2018 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
0
CY2017 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
0
CY2018 us-gaap Current Federal State And Local Tax Expense Benefit
CurrentFederalStateAndLocalTaxExpenseBenefit
20000
CY2017 us-gaap Current Federal State And Local Tax Expense Benefit
CurrentFederalStateAndLocalTaxExpenseBenefit
5000
CY2018 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
0
CY2017 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
0
CY2018 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
20000
CY2017 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
5000
CY2018 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
1167000
CY2017 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
5941000
CY2018 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
399000
CY2017 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
-320000
CY2018 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
60000
CY2017 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
0
CY2018 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0
CY2017 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0
CY2018 cyrx Operating Loss Carryforwards Percent
OperatingLossCarryforwardsPercent
0.8
CY2018 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
-1626000
CY2017 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
-5621000
CY2018 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
73400
CY2018Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
303000

Files In Submission

Name View Source Status
0001144204-19-013692-index-headers.html Edgar Link pending
0001144204-19-013692-index.html Edgar Link pending
0001144204-19-013692.txt Edgar Link pending
0001144204-19-013692-xbrl.zip Edgar Link pending
cyrx-20181231.xml Edgar Link completed
cyrx-20181231.xsd Edgar Link pending
cyrx-20181231_cal.xml Edgar Link unprocessable
cyrx-20181231_def.xml Edgar Link unprocessable
cyrx-20181231_lab.xml Edgar Link unprocessable
cyrx-20181231_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
image_001.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tv515562_10k.htm Edgar Link pending
tv515562_ex21.htm Edgar Link pending
tv515562_ex23-1.htm Edgar Link pending
tv515562_ex3-12.htm Edgar Link pending
tv515562_ex31-1.htm Edgar Link pending
tv515562_ex31-2.htm Edgar Link pending
tv515562_ex32-1.htm Edgar Link pending
tv515562_ex32-2.htm Edgar Link pending
tv515562_img1.jpg Edgar Link pending